1350456-56-2Relevant articles and documents
PHOSPHOLIPID ETHER CONJUGATES AS CANCER-TARGETING DRUG VEHICLES
-
Paragraph 000162, (2021/03/19)
Disclosed herein are therapeutic compounds capable of targeting a broad range of tumor cells. The present disclosure is further directed to compositions comprising the therapeutic compounds, methods of manufacturing the therapeutic compounds, and methods of treating cancer comprising administering the therapeutic compounds.
SELF-STABILIZING LINKER CONJUGATES
-
Paragraph 0551-0553, (2021/10/02)
The present invention provides Ligand-Drug Conjugates, Drug-Linkers, Linkers, and Ligand-Linker Conjugates comprising a self-stabilizing linker assembly component.
PROCESS FOR PREPARING INTERMEDIATE OF ANTIBODY DRUG CONJUGATE
-
Paragraph 0070-0073, (2020/05/29)
The present disclosure relates to a process for preparing an intermediate of antibody-drug conjugate. Compared with the conventional art, the process for preparing an intermediate of the antibody-drug conjugate provided by the present disclosure significantly reduces the feed loss for drug moiety, such as MMAD/MMAE or MMAF, etc., as drug moiety is involved in the last step of the reaction, thereby effectively reducing production costs, as well as increasing production efficiency. In addition, the process provided by the present disclosure is simple, environmentally friendly and suitable for large-scale industrialization.